CD8A and melanoma: EV-derived PD-L1 has been shown to elicit immunosuppressive effects similar to cellular PD-L1, which promotes immune evasion in melanoma tumors by inhibiting CD8+ T cell responses [160], where the blockade of PD-L1 induces systemic anti-tumor immunity [157,158].